Company Filing History:
Years Active: 2021-2024
Title: Inventor Spotlight: Angela Mackay
Introduction
Angela Mackay is an innovative inventor based in Basel, Switzerland. She is renowned for her contributions to the development of pharmaceutical compounds, specifically those targeting the NLRP3 inflammasome, a critical component in numerous diseases.
Latest Patents
Angela Mackay holds a total of four patents, with her latest inventions focusing on novel compounds designed to inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The first patent concerns thienopyrrolotriazinacetamide compounds, which are outlined in Formula (I). These compounds are aimed at treating various diseases and disorders mediated by NLRP3 through novel processes for their preparation and pharmaceutical compositions. Her second patent also pertains to inhibitors of the NLRP3 inflammasome, focusing on pyridazin-3-yl phenol compounds, again described in Formula (I). These compounds further emphasize the importance of NLRP3 in the treatment of related illnesses.
Career Highlights
Angela’s work is closely associated with Novartis AG, a prominent player in the pharmaceutical industry. Her role at the company allows her to engage in cutting-edge research and innovation in drug development.
Collaborations
Throughout her career, Angela has had the opportunity to collaborate with talented individuals like Christopher Farady and Nina Gommermann. Together, they contribute to advancing scientific knowledge and developing robust solutions in medical science.
Conclusion
Angela Mackay exemplifies the spirit of innovation and leadership in the field of pharmaceuticals. Her remarkable inventions not only demonstrate her expertise but also hold promising potentials for the treatment of significant health challenges associated with NLRP3 inflammasome activity. As she continues her work, the global medical community looks forward to the advancements that emerge from her research.